Rchr
J-GLOBAL ID:201801002378482764   Update date: Apr. 18, 2024

Aya Jibiki

ジビキ アヤ | Aya Jibiki
Affiliation and department:
Job title: Research Associate/Assistant Professor/Instructor
Research field  (1): Clinical pharmacy
Research keywords  (6): 骨粗鬆症 ,  医薬品の苦味マスキング ,  膠原病 ,  Kampo Medicine ,  更年期障害に対する薬物治療 ,  proper use of steroids, connective tissue disease, menopausal syndrome, osteoporosis, bitter-taste masking of medicine
Research theme for competitive and other funds  (4):
  • 2021 - 2022 更年期障害患者に対する最適な治療薬選択を目指したエストロゲン受容体遺伝子解析
  • 2018 - 2021 Analysis of factors influencing failure of treatment with harbal medicine for menopausal symptoms
  • 2019 - 2020 グルココルチコイド誘発性糖尿病患者におけるインスリン離脱困難例の要因分析
  • 2018 - 2020 グルココルチコイド誘発性糖尿病に対する薬物治療の洗練化と発症予測因子の検討
Papers (22):
  • Namiki T, Yokoyama Y, Hashi H, Oda R, Jibiki A, Kawazoe H, Matsumoto K, Suzuki S, Nakamura T. Pharmacokinetics/pharmacodynamics analysis and establishment of optimal dosing regimens using unbound cefmetazole concentration for patients infected with Extended-Spectrum β-lactamase producing Enterobacterales (ESBL-E). Pharmacotherapy. 2023
  • 石川春樹, 河添 仁, 岩田紘樹, 中村友紀, H地引 綾, HR, 横山雄太, 小林典子, 鈴木小夜, 山浦克典, et al. What factors improve the evaluation of achievement at the end of pharmacy practice experiences?. 医療薬学. 2023. 49. 4. 173-182
  • Emi Ishikawa, Yuta Yokoyama, Haruna Chishima, Hidefumi Kasai, Ouki Kuniyoshi, Motonori Kimura, Jun Hakamata, Hideo Nakada, Naoya Suehiro, Naoki Nakaya, et al. Population Pharmacokinetics, Pharmacogenomics, and Adverse Events of Osimertinib and its Two Active Metabolites, AZ5104 and AZ7550, in Japanese Patients with Advanced Non-small-cell Lung Cancer: a Prospective Observational Study. Investigational New Drugs. 2023. 41. 1. 122-133
  • Fumihiro Kikuyama, Sayo Suzuki, Aya Jibiki, Yuta Yokoyama, Hitoshi Kawazoe, Susumu Kitanaka, Tomonori Nakamura. Ingenol mebutate inhibits the growth of pancreatic cancer cells in vitro via STING with an efficacy comparable to that of clinically used anticancer agents. Journal of Natural Medicines. 2023. 77. 2. 343-351
  • Yokoyama Y, Nozawa E, Morita M, Ishikawa E, Mori T, Sakurai M, Kikuchi T, Matsuki E, Yamazaki R, Kataoka K, et al. Simultaneous quantification of dasatinib, nilotinib, bosutinib, and ponatinib using high-performance liquid chromatography-Photodiode array detection. Journal of Clinical Laboratory Analysis. 2022. 36. 8
more...
MISC (6):
  • Hitoshi Kawazoe, Sayo Suzuki, Yuta Yokoyama, Aya Jibiki, Tomonori Nakamura. がん薬物治療における職業性暴露対策の新たな動きと未来展望. Japanese Journal of Drug Safety. 2019. 5. 2. 67-76
  • Aya Jibiki, Yuta Yokoyama, Hitoshi Kawazoe, Sayo Suzuki, Tomonori Nakamura. Steroids as cancer medication. Japanese Journal of Drug Safety. 2019. 5. 1. 1-13
  • Sayo Suzuki, HJibiki Aya, HR,Yuta Yokoyama, Hitoshi Kawazoe, Tomonori Nakamura. Consideration of cancer treatments and clinical trials for special patient populations. Japanese Society of Drug Safety. 2018. 4. 2. 83-97
  • Yuta Yokoyama, Sayo Suzuki, HJibiki Aya, HR,Hitoshi Kawazoe, Tomonori Nakamura. Toward routine therapeutic drug monitoring of the epidermal growth factor receptor-the tyrosine kinase inhibitors. Japanese Society of Drug Safety. 2018. 4. 1. 3-13
  • クロピドグレルの効果に影響する因子は何か?. ファルマシア. 2009. 45. 11. 1142-1143
more...
Books (1):
  • こどもと薬のQ&A続
    じほう 2018
Lectures and oral presentations  (65):
  • 基質特異性拡張型β-ラクタマーゼ産生腸内細菌目細菌感染患者に対する遊離形セフメタゾール濃度を用いたPPK/PD解析と最適投与法の構築
    (第44回日本臨床薬理学会学術総会 2023)
  • 実務実習終了時における実習生の到達度評価を向上させる要因の検討
    (第33回日本医療薬学会年会 2023)
  • Population Pharmacokinetics, Pharmacogenomics, and Adverse Events of Osimertinib and its Two Active Metabolites, AZ5104 and AZ7550, in Japanese Patients with Advanced Non-small Cell Lung Cancer: A Prospective Observational Study
    (The 21th International Congress of Therapeutic Drug Monitoring & Clinical Toxicology 2023)
  • Investigating the effect of tacrolimus exposure on the acute rejection reaction after pediatric liver transplantation using population pharmacokinetic analysis
    (The 21th International Congress of Therapeutic Drug Monitoring & Clinical Toxicology 2023)
  • セフメタゾールに関連する国際標準比(INR)上昇のリスク因子特定と予測モデルの構築
    (第17回次世代を担う若手のための医療薬科学シンポジウム 2023)
more...
Education (2):
  • 2003 - 2005 Chiba University 大学院薬学研究院
  • 1999 - 2003 Meiji Pharmaceutical University 薬学部
Work history (2):
  • 2014/08 - 現在 Keio University, Faculty of Pharmacy Division of Pharmaceutical Care Sciences Research Associate
  • 2005/04 - 2014/07 University of Tsukuba Hospital Department of Pharmacy Chief
Awards (1):
  • 2023/02 - The Japanese Association for Gender-Specific Medicine Best Presentation Award 更年期症状に対する漢方治療不応例の分析
Association Membership(s) (9):
日本女性医学会 ,  Japan Society for Pharmaceutical Education ,  日本薬剤師会 ,  日本病院薬剤師会 ,  日本医療薬学会 ,  日本臨床薬理学会 ,  日本薬学会 ,  Japanese Society of Drug Safety ,  日本老年医学会
※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page